# Helaina

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/helaina

- Industry: Healthcare
- Headquarters: New York, US
- Website: www.myhelaina.com
- Total disclosed funding: $69M
- Latest round: Series B (Sep 25, 2024)
- Investors on record: 10

## About

Helaina Inc., based in the US, specializes in bioactive proteins, particularly Human Lactoferrin, designed to enhance nutrition and wellness through innovative technology.Founded in 2019 and headquartered in New York, Helaina Inc. focuses on developing bioactive proteins that replicate essential functions found naturally in the human body. Laura Katz serves as CEO, bringing industry experience to the company. Helaina has engaged in a total of 3 deals, with its most recent one taking place on September 25, 2024, during which the company raised USD 45.000 mn in a Series B funding round, led by Avidity Partners Management and supported by other investors including Spark Capital and Barrel Ventures. This funding round represents the total amount raised by the company to date, which is also USD 45.000 mn, while the current company valuation stands at USD 197.020 mn.Helaina's core product is the effera™ Human Lactoferrin, a bioactive protein that mimics proteins naturally found in the human body. This product aims to make vital nutrients more accessible, focusing on benefits such as improved iron utilization, gut health, and immune support. The company's offerings cater to a diverse clientele, including manufacturers in the dietary supplement and functional food sectors across North America and Europe.Helaina generates revenue primarily through partnerships with businesses in the dietary supplement and food industries that incorporate its effera™ Human Lactoferrin in their products. The company operates on a B2B basis, supplying its bioactive proteins under long-term contracts that allow partners to market finished goods to consumers. Effera™ is positioned as a premium ingredient to enhance nutritional value, although specific pricing details are not publicly disclosed.In September 2024, Helaina Inc. secured USD 45.000 mn in Series B funding, which will be utilized to scale the production and distribution of effera™ through strategic partnerships. The company plans to expand its reach into new consumer product markets, aiming for broader penetration and accessibility. This funding round will support the development of new products and enhance existing offerings, ensuring the company remains at the forefront of nutritional innovation.

## Funding rounds

- Series B, Sep 25, 2024, $45M — CF Private Equity, Primary Venture Partners, Spark Capital, SIAM Capital, Relish Works, Inc., Avidity Partners Management, Barrel Ventures, Ingeborg Investments
- Series A, Nov 19, 2021, $20M — Primary Venture Partners, Spark Capital, SIAM Capital, Plum Alley, Barrel Ventures, Cosmic VC
- Seed, Aug 19, 2020, $4M — Primary Venture Partners, Spark Capital

## Investors

- Primary Venture Partners (https://capitalatlas.ai/funds/primary-venture-partners) — Seed, Series A, Series B
- Spark Capital — Seed, Series A, Series B
- SIAM Capital — Series A, Series B
- Plum Alley (https://capitalatlas.ai/funds/plum-alley) — Series A
- Barrel Ventures (https://capitalatlas.ai/funds/barrel-ventures) — Series A, Series B
- Cosmic VC — Series A
- CF Private Equity (https://capitalatlas.ai/funds/cf-private-equity) — Series B
- Relish Works, Inc. — Series B
- Avidity Partners Management — Series B
- Ingeborg Investments (https://capitalatlas.ai/funds/ingeborg-investments) — Series B